Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy
Background The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV...
Gespeichert in:
Veröffentlicht in: | Journal of gastroenterology 2012-12, Vol.47 (12), p.1323-1335 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1335 |
---|---|
container_issue | 12 |
container_start_page | 1323 |
container_title | Journal of gastroenterology |
container_volume | 47 |
creator | Kondo, Yasuteru Ueno, Yoshiyuki Ninomiya, Masashi Tamai, Keiichi Tanaka, Yasuhito Inoue, Jun Kakazu, Eiji Kobayashi, Koju Kimura, Osamu Miura, Masahito Yamamoto, Takeshi Kobayashi, Tomoo Igarashi, Takehiko Shimosegawa, Tooru |
description | Background
The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV coinfected patients during pegylated interferon/ribavirin (Peg-IFN/RBV) therapy.
Methods
One patient with high HBV-DNA and high HCV-RNA titers (HBV-high/HCV-high) and 5 patients with low HBV-DNA and high HCV-RNA titers (HBV-low/HCV-high) were enrolled. Twenty patients monoinfected with HBV and 10 patients monoinfected with HCV were enrolled as control subjects.. In vitro cultures of Huh 7 cells with HBV/HCV dual infection were used to analyze the direct interaction of HBV/HCV.
Results
Direct interaction of HBV clones and HCV could not be detected in the Huh-7 cells. In the HBV-high/HCV-high-patient, the HCV-RNA level gradually declined and HBV-DNA gradually increased during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased at 1 month of Peg-IFN/RBV-therapy, but HBV-specific IFN-γ-secreting cells were not increased and HBV-specific interleukin (IL)-10 secreting cells were increased. The level of HBV- and HCV-specific IFN-γ-secreting cells in the HBV-high/HCV-high-patient was low in comparison to that in the HBV- or HCV-monoinfected patients. In the HBV-low/HCV-high-patient, HCV-RNA and HBV-DNA rapidly declined during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-γ-secreting cells were also increased during Peg-IFN/RBV-therapy.
Conclusion
The immunological responses of the HBV-high/HCV-high patient were low in comparison to the responses in HBV and HCV monoinfected patients. Moreover, the response of immune cells in the HBV-high/HCV-high patient during Peg-IFN/RBV therapy was insufficient to suppress HBV and HCV. |
doi_str_mv | 10.1007/s00535-012-0596-x |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1439235844</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714584946</galeid><sourcerecordid>A714584946</sourcerecordid><originalsourceid>FETCH-LOGICAL-c624t-c5a86e9979967d2966e29a18d9a3f88627bbf454cd5e9c71bcbe07636b3d5fb43</originalsourceid><addsrcrecordid>eNp1kUFr3DAUhEVoSTZpf0AvxdBLL8pKsiRbx2RpsoGQlqTdU0HI8vNWwbZcyYbsv6_MpklaWnQQenwzvNEg9I6SU0pIsYyEiFxgQhkmQkn8cIAWlKeJUIy9QguiOMeUFvwIHcd4TwjNiSgP0RFjoiwZlwv0_Q5-TtCPzrSZ67qp963fOptepjftLrqY-SZbn2-W69Umsx67vgE7Qp0NZnRJGLN6Cq7fZl9gi68ubpa355ts_AHBDLs36HVj2ghvH-8T9O3i09fVGl9_vrxanV1jKxkfsRWmlKBUoZQsaqakBKYMLWtl8qYsJSuqquGC21qAsgWtbAWkkLms8lo0Fc9P0Me97xB8ShNH3blooW1ND36KOv2JYrko-Yx--Au991NIURPFpBRyJp-prWlBp8h-DMbOpvqsoDw5KS4TdfoPKp0aOmd9D41L8z8EdC-wwccYoNFDcJ0JO02JnhvV-0Z1alTPjeqHpHn_uPBUdVA_KX5XmAC2B-Iw9wDhRaL_uv4CGsypKQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1266563923</pqid></control><display><type>article</type><title>Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Kondo, Yasuteru ; Ueno, Yoshiyuki ; Ninomiya, Masashi ; Tamai, Keiichi ; Tanaka, Yasuhito ; Inoue, Jun ; Kakazu, Eiji ; Kobayashi, Koju ; Kimura, Osamu ; Miura, Masahito ; Yamamoto, Takeshi ; Kobayashi, Tomoo ; Igarashi, Takehiko ; Shimosegawa, Tooru</creator><creatorcontrib>Kondo, Yasuteru ; Ueno, Yoshiyuki ; Ninomiya, Masashi ; Tamai, Keiichi ; Tanaka, Yasuhito ; Inoue, Jun ; Kakazu, Eiji ; Kobayashi, Koju ; Kimura, Osamu ; Miura, Masahito ; Yamamoto, Takeshi ; Kobayashi, Tomoo ; Igarashi, Takehiko ; Shimosegawa, Tooru</creatorcontrib><description>Background
The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV coinfected patients during pegylated interferon/ribavirin (Peg-IFN/RBV) therapy.
Methods
One patient with high HBV-DNA and high HCV-RNA titers (HBV-high/HCV-high) and 5 patients with low HBV-DNA and high HCV-RNA titers (HBV-low/HCV-high) were enrolled. Twenty patients monoinfected with HBV and 10 patients monoinfected with HCV were enrolled as control subjects.. In vitro cultures of Huh 7 cells with HBV/HCV dual infection were used to analyze the direct interaction of HBV/HCV.
Results
Direct interaction of HBV clones and HCV could not be detected in the Huh-7 cells. In the HBV-high/HCV-high-patient, the HCV-RNA level gradually declined and HBV-DNA gradually increased during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased at 1 month of Peg-IFN/RBV-therapy, but HBV-specific IFN-γ-secreting cells were not increased and HBV-specific interleukin (IL)-10 secreting cells were increased. The level of HBV- and HCV-specific IFN-γ-secreting cells in the HBV-high/HCV-high-patient was low in comparison to that in the HBV- or HCV-monoinfected patients. In the HBV-low/HCV-high-patient, HCV-RNA and HBV-DNA rapidly declined during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-γ-secreting cells were also increased during Peg-IFN/RBV-therapy.
Conclusion
The immunological responses of the HBV-high/HCV-high patient were low in comparison to the responses in HBV and HCV monoinfected patients. Moreover, the response of immune cells in the HBV-high/HCV-high patient during Peg-IFN/RBV therapy was insufficient to suppress HBV and HCV.</description><identifier>ISSN: 0944-1174</identifier><identifier>EISSN: 1435-5922</identifier><identifier>DOI: 10.1007/s00535-012-0596-x</identifier><identifier>PMID: 22588246</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Abdominal Surgery ; Adult ; Amino Acid Sequence ; Analysis ; Antiviral Agents - therapeutic use ; Biliary Tract ; Care and treatment ; Case-Control Studies ; CD4 antigen ; CD4-Positive T-Lymphocytes - drug effects ; CD4-Positive T-Lymphocytes - immunology ; CD8-Positive T-Lymphocytes - drug effects ; CD8-Positive T-Lymphocytes - immunology ; Cells, Cultured ; Coinfection - drug therapy ; Coinfection - immunology ; Colorectal Surgery ; Comorbidity ; Drug Therapy, Combination ; Gastroenterology ; Health aspects ; Hepacivirus - genetics ; Hepacivirus - isolation & purification ; Hepatitis B ; Hepatitis B virus ; Hepatitis B virus - genetics ; Hepatitis B virus - isolation & purification ; Hepatitis B, Chronic - complications ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - immunology ; Hepatitis C virus ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - immunology ; Hepatology ; Humans ; Immunity, Cellular - drug effects ; Infection ; Interferon ; Interferon-alpha - therapeutic use ; Interferon-gamma - biosynthesis ; Lymphocyte Activation - drug effects ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Original Article—Liver ; Pancreas ; Polyethylene Glycols - therapeutic use ; Recombinant Proteins - therapeutic use ; Ribavirin - therapeutic use ; RNA ; Surgical Oncology ; T cells</subject><ispartof>Journal of gastroenterology, 2012-12, Vol.47 (12), p.1323-1335</ispartof><rights>Springer 2012</rights><rights>COPYRIGHT 2012 Springer</rights><rights>Springer Japan 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c624t-c5a86e9979967d2966e29a18d9a3f88627bbf454cd5e9c71bcbe07636b3d5fb43</citedby><cites>FETCH-LOGICAL-c624t-c5a86e9979967d2966e29a18d9a3f88627bbf454cd5e9c71bcbe07636b3d5fb43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00535-012-0596-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00535-012-0596-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22588246$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kondo, Yasuteru</creatorcontrib><creatorcontrib>Ueno, Yoshiyuki</creatorcontrib><creatorcontrib>Ninomiya, Masashi</creatorcontrib><creatorcontrib>Tamai, Keiichi</creatorcontrib><creatorcontrib>Tanaka, Yasuhito</creatorcontrib><creatorcontrib>Inoue, Jun</creatorcontrib><creatorcontrib>Kakazu, Eiji</creatorcontrib><creatorcontrib>Kobayashi, Koju</creatorcontrib><creatorcontrib>Kimura, Osamu</creatorcontrib><creatorcontrib>Miura, Masahito</creatorcontrib><creatorcontrib>Yamamoto, Takeshi</creatorcontrib><creatorcontrib>Kobayashi, Tomoo</creatorcontrib><creatorcontrib>Igarashi, Takehiko</creatorcontrib><creatorcontrib>Shimosegawa, Tooru</creatorcontrib><title>Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy</title><title>Journal of gastroenterology</title><addtitle>J Gastroenterol</addtitle><addtitle>J Gastroenterol</addtitle><description>Background
The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV coinfected patients during pegylated interferon/ribavirin (Peg-IFN/RBV) therapy.
Methods
One patient with high HBV-DNA and high HCV-RNA titers (HBV-high/HCV-high) and 5 patients with low HBV-DNA and high HCV-RNA titers (HBV-low/HCV-high) were enrolled. Twenty patients monoinfected with HBV and 10 patients monoinfected with HCV were enrolled as control subjects.. In vitro cultures of Huh 7 cells with HBV/HCV dual infection were used to analyze the direct interaction of HBV/HCV.
Results
Direct interaction of HBV clones and HCV could not be detected in the Huh-7 cells. In the HBV-high/HCV-high-patient, the HCV-RNA level gradually declined and HBV-DNA gradually increased during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased at 1 month of Peg-IFN/RBV-therapy, but HBV-specific IFN-γ-secreting cells were not increased and HBV-specific interleukin (IL)-10 secreting cells were increased. The level of HBV- and HCV-specific IFN-γ-secreting cells in the HBV-high/HCV-high-patient was low in comparison to that in the HBV- or HCV-monoinfected patients. In the HBV-low/HCV-high-patient, HCV-RNA and HBV-DNA rapidly declined during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-γ-secreting cells were also increased during Peg-IFN/RBV-therapy.
Conclusion
The immunological responses of the HBV-high/HCV-high patient were low in comparison to the responses in HBV and HCV monoinfected patients. Moreover, the response of immune cells in the HBV-high/HCV-high patient during Peg-IFN/RBV therapy was insufficient to suppress HBV and HCV.</description><subject>Abdominal Surgery</subject><subject>Adult</subject><subject>Amino Acid Sequence</subject><subject>Analysis</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biliary Tract</subject><subject>Care and treatment</subject><subject>Case-Control Studies</subject><subject>CD4 antigen</subject><subject>CD4-Positive T-Lymphocytes - drug effects</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD8-Positive T-Lymphocytes - drug effects</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Cells, Cultured</subject><subject>Coinfection - drug therapy</subject><subject>Coinfection - immunology</subject><subject>Colorectal Surgery</subject><subject>Comorbidity</subject><subject>Drug Therapy, Combination</subject><subject>Gastroenterology</subject><subject>Health aspects</subject><subject>Hepacivirus - genetics</subject><subject>Hepacivirus - isolation & purification</subject><subject>Hepatitis B</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B virus - genetics</subject><subject>Hepatitis B virus - isolation & purification</subject><subject>Hepatitis B, Chronic - complications</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - immunology</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - immunology</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Immunity, Cellular - drug effects</subject><subject>Infection</subject><subject>Interferon</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Interferon-gamma - biosynthesis</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Original Article—Liver</subject><subject>Pancreas</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Ribavirin - therapeutic use</subject><subject>RNA</subject><subject>Surgical Oncology</subject><subject>T cells</subject><issn>0944-1174</issn><issn>1435-5922</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kUFr3DAUhEVoSTZpf0AvxdBLL8pKsiRbx2RpsoGQlqTdU0HI8vNWwbZcyYbsv6_MpklaWnQQenwzvNEg9I6SU0pIsYyEiFxgQhkmQkn8cIAWlKeJUIy9QguiOMeUFvwIHcd4TwjNiSgP0RFjoiwZlwv0_Q5-TtCPzrSZ67qp963fOptepjftLrqY-SZbn2-W69Umsx67vgE7Qp0NZnRJGLN6Cq7fZl9gi68ubpa355ts_AHBDLs36HVj2ghvH-8T9O3i09fVGl9_vrxanV1jKxkfsRWmlKBUoZQsaqakBKYMLWtl8qYsJSuqquGC21qAsgWtbAWkkLms8lo0Fc9P0Me97xB8ShNH3blooW1ND36KOv2JYrko-Yx--Au991NIURPFpBRyJp-prWlBp8h-DMbOpvqsoDw5KS4TdfoPKp0aOmd9D41L8z8EdC-wwccYoNFDcJ0JO02JnhvV-0Z1alTPjeqHpHn_uPBUdVA_KX5XmAC2B-Iw9wDhRaL_uv4CGsypKQ</recordid><startdate>20121201</startdate><enddate>20121201</enddate><creator>Kondo, Yasuteru</creator><creator>Ueno, Yoshiyuki</creator><creator>Ninomiya, Masashi</creator><creator>Tamai, Keiichi</creator><creator>Tanaka, Yasuhito</creator><creator>Inoue, Jun</creator><creator>Kakazu, Eiji</creator><creator>Kobayashi, Koju</creator><creator>Kimura, Osamu</creator><creator>Miura, Masahito</creator><creator>Yamamoto, Takeshi</creator><creator>Kobayashi, Tomoo</creator><creator>Igarashi, Takehiko</creator><creator>Shimosegawa, Tooru</creator><general>Springer Japan</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U9</scope></search><sort><creationdate>20121201</creationdate><title>Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy</title><author>Kondo, Yasuteru ; Ueno, Yoshiyuki ; Ninomiya, Masashi ; Tamai, Keiichi ; Tanaka, Yasuhito ; Inoue, Jun ; Kakazu, Eiji ; Kobayashi, Koju ; Kimura, Osamu ; Miura, Masahito ; Yamamoto, Takeshi ; Kobayashi, Tomoo ; Igarashi, Takehiko ; Shimosegawa, Tooru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c624t-c5a86e9979967d2966e29a18d9a3f88627bbf454cd5e9c71bcbe07636b3d5fb43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Abdominal Surgery</topic><topic>Adult</topic><topic>Amino Acid Sequence</topic><topic>Analysis</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biliary Tract</topic><topic>Care and treatment</topic><topic>Case-Control Studies</topic><topic>CD4 antigen</topic><topic>CD4-Positive T-Lymphocytes - drug effects</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD8-Positive T-Lymphocytes - drug effects</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Cells, Cultured</topic><topic>Coinfection - drug therapy</topic><topic>Coinfection - immunology</topic><topic>Colorectal Surgery</topic><topic>Comorbidity</topic><topic>Drug Therapy, Combination</topic><topic>Gastroenterology</topic><topic>Health aspects</topic><topic>Hepacivirus - genetics</topic><topic>Hepacivirus - isolation & purification</topic><topic>Hepatitis B</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B virus - genetics</topic><topic>Hepatitis B virus - isolation & purification</topic><topic>Hepatitis B, Chronic - complications</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - immunology</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - immunology</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Immunity, Cellular - drug effects</topic><topic>Infection</topic><topic>Interferon</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Interferon-gamma - biosynthesis</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Original Article—Liver</topic><topic>Pancreas</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Ribavirin - therapeutic use</topic><topic>RNA</topic><topic>Surgical Oncology</topic><topic>T cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kondo, Yasuteru</creatorcontrib><creatorcontrib>Ueno, Yoshiyuki</creatorcontrib><creatorcontrib>Ninomiya, Masashi</creatorcontrib><creatorcontrib>Tamai, Keiichi</creatorcontrib><creatorcontrib>Tanaka, Yasuhito</creatorcontrib><creatorcontrib>Inoue, Jun</creatorcontrib><creatorcontrib>Kakazu, Eiji</creatorcontrib><creatorcontrib>Kobayashi, Koju</creatorcontrib><creatorcontrib>Kimura, Osamu</creatorcontrib><creatorcontrib>Miura, Masahito</creatorcontrib><creatorcontrib>Yamamoto, Takeshi</creatorcontrib><creatorcontrib>Kobayashi, Tomoo</creatorcontrib><creatorcontrib>Igarashi, Takehiko</creatorcontrib><creatorcontrib>Shimosegawa, Tooru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Virology and AIDS Abstracts</collection><jtitle>Journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kondo, Yasuteru</au><au>Ueno, Yoshiyuki</au><au>Ninomiya, Masashi</au><au>Tamai, Keiichi</au><au>Tanaka, Yasuhito</au><au>Inoue, Jun</au><au>Kakazu, Eiji</au><au>Kobayashi, Koju</au><au>Kimura, Osamu</au><au>Miura, Masahito</au><au>Yamamoto, Takeshi</au><au>Kobayashi, Tomoo</au><au>Igarashi, Takehiko</au><au>Shimosegawa, Tooru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy</atitle><jtitle>Journal of gastroenterology</jtitle><stitle>J Gastroenterol</stitle><addtitle>J Gastroenterol</addtitle><date>2012-12-01</date><risdate>2012</risdate><volume>47</volume><issue>12</issue><spage>1323</spage><epage>1335</epage><pages>1323-1335</pages><issn>0944-1174</issn><eissn>1435-5922</eissn><abstract>Background
The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV coinfected patients during pegylated interferon/ribavirin (Peg-IFN/RBV) therapy.
Methods
One patient with high HBV-DNA and high HCV-RNA titers (HBV-high/HCV-high) and 5 patients with low HBV-DNA and high HCV-RNA titers (HBV-low/HCV-high) were enrolled. Twenty patients monoinfected with HBV and 10 patients monoinfected with HCV were enrolled as control subjects.. In vitro cultures of Huh 7 cells with HBV/HCV dual infection were used to analyze the direct interaction of HBV/HCV.
Results
Direct interaction of HBV clones and HCV could not be detected in the Huh-7 cells. In the HBV-high/HCV-high-patient, the HCV-RNA level gradually declined and HBV-DNA gradually increased during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased at 1 month of Peg-IFN/RBV-therapy, but HBV-specific IFN-γ-secreting cells were not increased and HBV-specific interleukin (IL)-10 secreting cells were increased. The level of HBV- and HCV-specific IFN-γ-secreting cells in the HBV-high/HCV-high-patient was low in comparison to that in the HBV- or HCV-monoinfected patients. In the HBV-low/HCV-high-patient, HCV-RNA and HBV-DNA rapidly declined during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-γ-secreting cells were also increased during Peg-IFN/RBV-therapy.
Conclusion
The immunological responses of the HBV-high/HCV-high patient were low in comparison to the responses in HBV and HCV monoinfected patients. Moreover, the response of immune cells in the HBV-high/HCV-high patient during Peg-IFN/RBV therapy was insufficient to suppress HBV and HCV.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>22588246</pmid><doi>10.1007/s00535-012-0596-x</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0944-1174 |
ispartof | Journal of gastroenterology, 2012-12, Vol.47 (12), p.1323-1335 |
issn | 0944-1174 1435-5922 |
language | eng |
recordid | cdi_proquest_miscellaneous_1439235844 |
source | MEDLINE; SpringerLink Journals |
subjects | Abdominal Surgery Adult Amino Acid Sequence Analysis Antiviral Agents - therapeutic use Biliary Tract Care and treatment Case-Control Studies CD4 antigen CD4-Positive T-Lymphocytes - drug effects CD4-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - drug effects CD8-Positive T-Lymphocytes - immunology Cells, Cultured Coinfection - drug therapy Coinfection - immunology Colorectal Surgery Comorbidity Drug Therapy, Combination Gastroenterology Health aspects Hepacivirus - genetics Hepacivirus - isolation & purification Hepatitis B Hepatitis B virus Hepatitis B virus - genetics Hepatitis B virus - isolation & purification Hepatitis B, Chronic - complications Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - immunology Hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - immunology Hepatology Humans Immunity, Cellular - drug effects Infection Interferon Interferon-alpha - therapeutic use Interferon-gamma - biosynthesis Lymphocyte Activation - drug effects Male Medicine Medicine & Public Health Middle Aged Original Article—Liver Pancreas Polyethylene Glycols - therapeutic use Recombinant Proteins - therapeutic use Ribavirin - therapeutic use RNA Surgical Oncology T cells |
title | Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T07%3A06%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sequential%20immunological%20analysis%20of%20HBV/HCV%20co-infected%20patients%20during%20Peg-IFN/RBV%20therapy&rft.jtitle=Journal%20of%20gastroenterology&rft.au=Kondo,%20Yasuteru&rft.date=2012-12-01&rft.volume=47&rft.issue=12&rft.spage=1323&rft.epage=1335&rft.pages=1323-1335&rft.issn=0944-1174&rft.eissn=1435-5922&rft_id=info:doi/10.1007/s00535-012-0596-x&rft_dat=%3Cgale_proqu%3EA714584946%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1266563923&rft_id=info:pmid/22588246&rft_galeid=A714584946&rfr_iscdi=true |